Viewing Study NCT05548660


Ignite Creation Date: 2025-12-25 @ 2:07 AM
Ignite Modification Date: 2026-01-07 @ 3:40 PM
Study NCT ID: NCT05548660
Status: COMPLETED
Last Update Posted: 2025-04-11
First Post: 2022-09-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pharmacogenetic-guided Choice of Post-surgery Analgesics
Sponsor: University of Pennsylvania
Organization:

Study Overview

Official Title: Pharmacogenetic-guided Choice of Post-surgery Analgesics
Status: COMPLETED
Status Verified Date: 2025-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PRECISE
Brief Summary: Pharmacogenomics (PGx) is the study of how genes affect a person's response to drugs. PGx testing for certain genes can help predict the risk of side effects or therapeutic failure from analgesics. Testing is not regularly performed in clinical practice due to long wait times for results and challenges with integrating test results in the electronic health record. Investigators leading this study hope to find out if providing surgeons with the ability to order a PGx test and electronically receive results with dosing recommendations will increase the use of these tests to guide analgesic choice and improve patient outcomes.

This is a prospective, two-arm randomized implementation study. Eligible participants will be randomly assigned to receive genotype-guided analgesic selection (intervention arm) or usual care (control arm). Both cohorts will undergo pharmacogenetic testing at the time of consenting. The investigators will primarily measure the feasibility of using this test to guide analgesic selection.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: